Surrey & North West Sussex Area Prescribing Committee

Policy Statement	Teriparatide for all CCG-commissioned indications
Policy No:	APC 462-2019
Date of Issue	November 2019
Review Date:	*No review date will be assigned to any drugs or devices that are subject to a NICE Technology appraisal.* *The recommendation made by the APC (formerly PCN) will be reviewed when new published evidence becomes available OR there is new published national guidance e.g. NICE)*

Recommendations:

The APC recommends the use of biosimilar teriparatide in all new patients for all CCG-commissioned indications.
Teriparatide is considered as RED on the traffic light system.

Prescribing would be by hospital specialists only, in line with NICE and using the Blueteq initiation and repeat treatment forms.

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.

Please note; the Medicines Healthcare Products Regulatory Agency (MHRA) recommends that to prescribe biological products by brand name to ensure that substitution of a substitution of a biosimilar product does not occur when the medicine is dispensed by the pharmacist.
https://www/gov/uk/drug-safety-update/biosimilar-products

Key Considerations:

- The choice of biosimilar brand used at provider trusts will be dependent on regional Commercial Medicines Unit (CMU) tender processes and trust preference.
- Biosimilar teriparatide could provide potential savings to the health economy

Date taken to Area Prescribing Committee	6th November 2019
Agreed by APC members	19th November 2019